特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
923129

インスリン非注射製剤

Non-injectable Insulin

出版日: | 発行: BCC Research | ページ情報: 英文 54 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
インスリン非注射製剤
出版日: 2020年01月22日
発行: BCC Research
ページ情報: 英文 54 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、インスリン非注射製剤市場について調査し、成長の促進要因、抑制要因、機会および動向といった市場の成長に影響を及ぼす市場ダイナミクスの分析、形状・原料・地域別の分析、競合情勢の分析、および主要企業のプロファイルなどを提供しています。

第1章 イントロダクション

第2章 サマリーとハイライト

第3章 市場と技術の背景

  • 市場潜在性・投資分析
  • 北米は最大かつ最も成長の速い市場となる

第4章 市場分析:形状別

  • 錠剤
  • スプレー
  • その他(フィルム・チューインガム)

第5章 市場分析:原料別

  • 合成インスリン
  • 半合成インスリン

第6章 市場分析:地域別

  • 北米
  • 米国
  • カナダ
  • 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
  • アジア太平洋
  • 中国
  • インド
  • 日本
  • その他のアジア太平洋
  • その他の地域

第7章 競合情勢

第8章 企業プロファイル

  • ACCESS PHARMACEUTICALS INC. (ABEONA THERAPEUTICS INC.)
  • AERAMI THERAPEUTICS
  • BIOCON LTD.
  • BIODEL INC. (ALBIREO LTD.)
  • BIONOVA LIFESCIENCES
  • BOSTON THERAPEUTICS INC.
  • COROMED INC.
  • DIABETOLOGY LTD.
  • DIASOME PHARMACEUTICALS INC.
  • EMISPHERE TECHNOLOGIES INC.
  • GENEREX BIOTECHNOLOGY CORP.
  • MIDATECH PHARMA PLC
  • ORAMED PHARMACEUTICALS INC.
  • RANI THERAPEUTICS
  • SHREYA LIFE SCIENCES PVT. LTD.
図表

List of Tables

  • Summary Table: Global Market for Non-injectable Insulin, by Region, Through 2024
    • Table 1: Other Products Related to Non-injectable Insulin
    • Table 2: Examples of Non-injectable Insulin Products
    • Table 3: Global Market for Non-injectable Insulin, by Form, Through 2024
    • Table 4: Global Market for Edible Insulin Pills, by Region, Through 2024
    • Table 5: Global Market for Insulin Sprays, by Region, Through 2024
    • Table 6: Global Market for Other Forms of Non-injectable Insulin, by Region, Through 2024
    • Table 7: Global Market for Non-injectable Insulin, by Source, Through 2024
    • Table 8: Global Market for Synthetic Non-injectable Insulin, by Region, Through 2024
    • Table 9: Global Market for Semisynthetic Non-injectable Insulin, by Region, Through 2024
    • Table 10: Global Market for Non-injectable Insulin, by Region, Through 2024
    • Table 11: Top 10 Countries with the Highest Prevalence of Diabetes Across the Globe, 2019
    • Table 12: North American Market for Non-injectable Insulin, by Form, Through 2024
    • Table 13: North American Market for Non-injectable Insulin, by Source, Through 2024
    • Table 14: Prevalence of Diabetes in North American Countries, 2010-2017
    • Table 15: Prevalence of Diabetes in North America, 2019-2045
    • Table 16: Prevalence of Diabetes in Europe, 2019-2045
    • Table 17: European Market for Non-injectable Insulin, by Form, Through 2024
    • Table 18: European Market for Non-injectable Insulin, by Source, Through 2024
    • Table 19: Existing National Diabetes Plans in Europe, by Country
    • Table 20: Prevalence of Diabetes in Asia-Pacific, 2019-2045
    • Table 21: Asia-Pacific Market for Non-injectable Insulin, by Form, Through 2024
    • Table 22: Asia-Pacific Market for Non-injectable Insulin, by Source, Through 2024
    • Table 23: Rest of the World Market for Non-injectable Insulin, by Form, Through 2024
    • Table 24: Rest of the World Market for Non-injectable Insulin, by Source, Through 2024

List of Figures

  • Summary Figure: Global Market for Non-injectable Insulin, by Region, 2018-2024
    • Figure 1: Global Prevalence of Diabetes in the 20-79 Year Age Group, 2011-2045*
    • Figure 2: Global Diabetes Prevalence, 2019-2045
    • Figure 3: Novo Nordisk Revenue Share, by Region, 2018
    • Figure 4: Eli Lilly Revenue Share, by Segment, 2018
    • Figure 5: Nektar Therapeutics Revenue Share, by Region, 2018
目次
Product Code: PHM224A

Report Highlights:

This comprehensive report provides an in-depth assessment of the global market for non-injectable insulin. The report's key objective is to analyze areas of opportunities, key developments and the impact of this technology on industry, specifically the pharmaceutical, biotechnology and healthcare sectors. The analysis also reviews the adoption of non-injectable insulin in developed and emerging markets.

Report Scope:

The report provides a comprehensive summary of the Non-injectable insulin market, along with detailed profiles of key market players that include revenue product portfolios and recent activities. The report analyzes trends and dynamics, including drivers, limitations, challenges and opportunities. The report discusses strategies adopted by emerging market players, with recommendations for new market entrants. This research study discusses historical, current and potential market size. The report will help market players and new entrants make informed decisions about the production and export of goods and services. Organizations, distributors and exporters should find the information about market development and trends useful. The study segments the market according to applications and end uses. Geographical market analysis is provided for all major segments.

Report Includes:

  • An overview of the global market for non-injectable insulin
  • Analyses of market trends, with data from 2018, 2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Information on recent major technical advances in different forms of non-injectable insulin
  • A look at the key areas of growth and adoption rate of non-injectable insulin among both commercial customers and regulatory authorities
  • Examination of strategies of the major players in the market and the impact of new technological developments

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Future Market Potential and Investment Analysis
  • North America Will be the Largest and Fastest-Growing Market

Chapter 4: Market Breakdown by Form

  • Pills
  • Spray
  • Others (Film and Chewing Gum)

Chapter 5: Market Breakdown by Source

  • Synthetic Insulin
  • Semisynthetic Insulin

Chapter 6: Market Breakdown by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Rest of Asia-Pacific
  • Rest of the World

Chapter 7: Competitive Landscape

Chapter 8: Company Profiles

  • ACCESS PHARMACEUTICALS INC. (ABEONA THERAPEUTICS INC.)
  • AERAMI THERAPEUTICS
  • BIOCON LTD.
  • BIODEL INC. (ALBIREO LTD.)
  • BIONOVA LIFESCIENCES
  • BOSTON THERAPEUTICS INC.
  • COROMED INC.
  • DIABETOLOGY LTD.
  • DIASOME PHARMACEUTICALS INC.
  • EMISPHERE TECHNOLOGIES INC.
  • GENEREX BIOTECHNOLOGY CORP.
  • MIDATECH PHARMA PLC
  • ORAMED PHARMACEUTICALS INC.
  • RANI THERAPEUTICS
  • SHREYA LIFE SCIENCES PVT. LTD.
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.